acid-phosphatase and Remission--Spontaneous

Topics: Acid Phosphatase; Adult; Aged; Alkaline Phosphatase; Bone Marrow Cells; Cerebral Hemorrhage; Daunorubicin; Female; Gastrointestinal Hemorrhage; Glucuronidase; Humans; Leukemia; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocytes; Male; Middle Aged; Monocytes; Muramidase; Naphthol AS D Esterase; Periodic Acid-Schiff Reaction; Peroxidases; Pregnancy; Prognosis; Remission, Spontaneous

Topics: 17-Ketosteroids; Acid Phosphatase; Adrenalectomy; Adrenocorticotropic Hormone; Animals; Castration; Cortisone; Gold Isotopes; Growth Hormone; Humans; Hypophysectomy; Luteinizing Hormone; Male; Pituitary Irradiation; Prolactin; Prostate; Prostatic Neoplasms; Radioisotopes; Rats; Remission, Spontaneous

Estramustine phosphate (Estracyt) was used in the treatment of 154 patients with carcinoma of the prostate in stage IV. Sixty-three patients were given Estracyt from the outset (primary treatment group) and 91 had previously received some other endocrine therapy (secondary treatment group). All of the patients were observed for more than one year. The drug was given intravenously and/or orally. Objective remissions occurred in 46 (73.0%) of the 63 patients in the primary treatment group and subjective remissions in all the objective responders and in 12 additional patients (92.0%). The corresponding figures for the secondary treatment group were 28 (30.7%) and 52 (57.1%) of 91. The side-effects were negligible, and the drug was well tolerated. No cumulative toxic effect was observed in patients who had been receiving the treatment for more than five years. In our opinion the compound is valuable in the treatment of advanced prostatic carcinoma (stage IV).

Topics: Acid Phosphatase; Administration, Oral; Clinical Trials as Topic; Drug Evaluation; Estramustine; Follow-Up Studies; Humans; Injections, Intravenous; Male; Nitrogen Mustard Compounds; Prostatic Neoplasms; Remission, Spontaneous

Acid phosphatase (AP) activity of plasma cells was studied in 38 patients with multiple myeloma (MM). The average activity per cell was strong (mean score = 2.42; maximum score = 4) and the percentage of positive cells was greater than 90% in over 71% of patients. The average AP activity per cell was higher prior to treatment (3.06 +/- 0.53) compared to relapse (2.48 +/- 0.77) and remission (1.81 +/- 1.02 (p less than 0.05 and p less than 0.01, respectively). In correlation of AP activity with clinical features at the time of the study, the only significant difference was between kappa and lambda subtype. Patients with lambda MM had a higher average AP activity per cell in remission (2.71 +/- 0.43) as opposed to kappa MM (1.17 +/- 1.06, p less than 0.05 for difference). AP activity was not significantly correlated with degree of bone involvement. However, activity seemed to be a good marker of disease activity.

Topics: Acid Phosphatase; Aged; Aging; Bone Marrow; Calcium; Female; Hemoglobins; Humans; Immunoglobulin Light Chains; Immunoglobulins; Male; Middle Aged; Multiple Myeloma; Plasma Cells; Remission, Spontaneous

Topics: Acid Phosphatase; Aged; Drug Evaluation; Humans; Male; Melphalan; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Remission, Spontaneous

Topics: Acid Phosphatase; Adenocarcinoma; Aged; Humans; Male; Melphalan; Middle Aged; Prostatic Neoplasms; Remission, Spontaneous; Time Factors

Topics: Acid Phosphatase; Adolescent; Alkaline Phosphatase; Child; Child, Preschool; Clinical Enzyme Tests; Enzyme Activation; Humans; Infant; Neurodermatitis; Neutrophils; Prognosis; Pyoderma; Remission, Spontaneous; Seasons

Topics: Acid Phosphatase; Acute Disease; Adult; alpha-Macroglobulins; Asthma; Humans; Lymphocyte Activation; Lymphocytes; Male; Remission, Spontaneous

Topics: Acid Phosphatase; Adenocarcinoma; Adult; Aged; Castration; Estradiol Congeners; Humans; Lymphatic Metastasis; Male; Middle Aged; Prostatic Neoplasms; Radiation Injuries; Radiotherapy Dosage; Remission, Spontaneous; Time Factors

Serial bone scans and radiographic surveys were performed in 167 patients with histologically proven carcinoma of the prostate: 435 scans and surveys were performed. Nineteen of 99 patients with negative findings on diagnosis have become positive on follow-up. Forty-nine patients had positive findings on presentation; 8 have regressed on follow-up and 26 have progressed; 15 have remained unchanged. This is a sensitive method of follow-up in patients with carcinoma of prostate. Changes occurred in bone scans and skeletal surveys before any alteration in serum acid or alkaline phosphatases, symptoms of metastases or change in prostatic size in the majority of cases. The documentation of progression from MO to M1 disease presents no problems. However, problems in quantitation may arise in patients presenting with M1 disease.

Topics: Acid Phosphatase; Alkaline Phosphatase; Bone Neoplasms; Follow-Up Studies; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Radiography; Radionuclide Imaging; Remission, Spontaneous

29 cases of T-cell derived lymphoblastic lymphoma and T-ALL have been analyzed. There is a striking prevalence of the male sex. In the peripheral blood we often find initially an excessive number of white blood cells combined with normal values for the other constituents in about half of the patients; This may be an expression for the rapid occurrence of leukaemia in T-cell lymphosarcoma. In addition to systemic ALL-therapy we performed X-ray irradiation of the mediastinum in 8 of our patients. This yielded to significantly longer first complete remissions. All patients with T-cell LSA/ALL with or without mediastinal mass should be treated in this manner. Cytochemically a strong focal acid phosphatase reaction was found to be acharacteristic of these cells. It has proved to be a screening method for this disease. The cells are T-cell derived and their pattern of surface markers is similar to that found in fetal thymocytes.

Topics: Acid Phosphatase; Adolescent; Age Factors; Child; Child, Preschool; Female; Histocytochemistry; Humans; Leukemia, Lymphoid; Lymphocytes; Lymphoma; Male; Mediastinal Neoplasms; Remission, Spontaneous; Sex Factors; T-Lymphocytes

Since 1970 a total of 107 patients has been treated radically with radiation therapy for carcinoma of the prostate. The local control with this form of treatment is over 90%. The five year actuarial survival is 74% and the disease-free survival 58%. Serious morbidity has been minimal. Survival is related to the extent of initial involvement and the histology of the tumor, but is not influenced by elevation of the acid phosphatase. Radical radiation therapy is an effective method of local control for carcinoma of the prostate and is potentially curative.

Topics: Acid Phosphatase; Aged; Digestive System; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Radiation Dosage; Radiotherapy, High-Energy; Remission, Spontaneous; Time Factors; Urinary Tract

Ureteral obstruction occurred in 10% of the patients treated for prostatic carcinoma and most often was associated with poorly differentiated tumors. The response of ureteral obstruction to different forms of therapy was evaluated. Obstruction diminished in 22 of 25 orchiectomized patients (88%) but in only 1 of 6 patients receiving estrogen or antiandrogen therapy alone (17%). Patients who responded favorably to therapy had a significantly better survival than did non-responders. Patients treated early in the course of ureteral obstruction responded better than those treated late, while neither tumor stage nor grade correlated with response to therapy. Radiation therapy for endocrine-resistant ureteral obstruction was effective in only 2 of 8 cases (25%). The literature on ureteral obstruction from prostatic carcinoma and its treatment is reviewed.

Topics: Acid Phosphatase; Androgen Antagonists; Castration; Cyproterone; Diethylstilbestrol; Estrogens; Humans; Male; Maryland; Prostatic Neoplasms; Remission, Spontaneous; Time Factors; Ureteral Obstruction

From 63 children with acute leukaemia the bone-marrow smears were cytochemically examined before the beginning of therapy. The activity of peroxydase was examined according to Sato and Sekya, that of acid phosphatase according to Löffler and Berghoff, that of alpha-naphthyl-acetate-esterase according to Gomori; the evidence of glycogen was examined by means of the PAS-diastase response according to McManus. Among the 63 cases of leukaemia we found 6 cases of paramyeloblastic leukaemia, 2 cases of parapromyelocytic leukaemia, and 3 cases of myelomonocytic leukaemia. 52 cases of leukaemia could not be further differentiated in morphological respect. They represented an immature paraleukoblastic leukaemia. A division according to leading cytochemical criteria was made for them. The therapeutic possibility of influencing the various groups was checked by means of prolonged observations. Children affected with paraleukoblastic leukaemia of the phosphatase type had a significantly low rate of remission similar to the myeloid leukaemia. Paraleukoblastic leukaemia of the PAS type, esterase type and the undifferentiated type revealed no essential differences. The rate of remission, however, was highest in leukaemia of the PAS type amounting to 100%. In one part of patients the prolonged cytochemical observations in 8 children with recidives showed that the cytochemical type under chemotherapy was changed.

Topics: Acid Phosphatase; Acute Disease; Bone Marrow; Bone Marrow Cells; Child; Esterases; Glycogen; Histocytochemistry; Humans; Leukemia; Leukocytes; Peroxidases; Remission, Spontaneous

Topics: Acid Phosphatase; Acute Disease; Adult; Allergens; Asthma; Bacteria; Chronic Disease; Clinical Enzyme Tests; Humans; Hypersensitivity; Leukocytes; Middle Aged; Remission, Spontaneous; Skin Tests

Topics: Acid Phosphatase; Cyclophosphamide; Cytarabine; Drug Therapy, Combination; Fluorescent Antibody Technique; Glucuronidase; Histocytochemistry; Humans; Immunoelectrophoresis; Immunoglobulin Fragments; Karyotyping; Leukemia, Plasma Cell; Male; Melphalan; Microscopy, Electron; Microscopy, Fluorescence; Middle Aged; Plasma Cells; Prednisone; Prognosis; Remission, Spontaneous; Staining and Labeling; Vincristine

Topics: Acid Phosphatase; Animals; Body Weight; Cardiomegaly; Cathepsins; Creatine Kinase; Disease Models, Animal; Heart Ventricles; Hexosaminidases; Hyperthyroidism; Lysosomes; Male; Myocardium; Organ Size; Proteins; Rats; Remission, Spontaneous; Thyroxine

Acute promyelocytic leukaemia (A.P.L.) is a rare but important type of acute myeloid leukaemia characterized by major bleeding in association with thrombocytopenia, a specific peripheral blood and bone marrow picture, low plasma fibrinogen, and the presence in the serum of fibrin degradation products. These last abnormalities are related to the disseminated intravascular consumption of coagulation factors with secondary fibrinolysis. A.P.L. requires early recognition and urgent treatment. With optimal management up to half of the patients may achieve complete remission of two years or more. Undoubtedly patients with A.P.L. do especially well when treated in special centres and some patients with A.P.L. now die before the nature of their disease is recognized. Increased familiarity with the problem, which has been known for nearly 20 years, should yield great dividends for those few patients who have this disease.

Topics: Acid Phosphatase; Binding Sites; Bone Marrow Cells; Erythrocytes; Factor V; Factor VIII; Fibrinogen; Hematuria; Hemorrhage; Heparin; Humans; Leukemia, Myeloid; Leukocyte Count; Peroxidases; Platelet Transfusion; Prognosis; Prothrombin; Purpura; Remission, Spontaneous; Thrombocytopenia; Vitamin B 12

Topics: 17-Ketosteroids; Acid Phosphatase; Adrenalectomy; Aged; Alkaline Phosphatase; Bone Neoplasms; Castration; Estrogens; Evaluation Studies as Topic; Humans; Hypophysectomy; Male; Middle Aged; Neoplasm Metastasis; Pennsylvania; Prognosis; Prostatic Neoplasms; Radiography; Recurrence; Remission, Spontaneous; Testosterone

Topics: Acid Phosphatase; Age Factors; Animals; Bone and Bones; Bone Development; Bone Matrix; Bone Resorption; Calcium; Collagen; Cytoplasm; Injections, Intraperitoneal; Lysosomes; Osteoclasts; Osteopetrosis; Proline; Rats; Remission, Spontaneous; Time Factors; Tritium

Topics: Acid Phosphatase; Adult; Aged; Alkaline Phosphatase; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Female; Hematologic Diseases; Humans; Injections, Intravenous; Male; Middle Aged; Movement; Multiple Myeloma; Neoplasm Metastasis; Pain, Intractable; Radionuclide Imaging; Remission, Spontaneous; Strontium Radioisotopes; Urinary Bladder Neoplasms; Uterine Neoplasms

Topics: 17-Ketosteroids; Acid Phosphatase; Aged; Alkaline Phosphatase; Anesthesia, Local; Castration; Cortisone; Cryosurgery; Estrogens; Follicle Stimulating Hormone; Humans; Hypophysectomy; Luteinizing Hormone; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Prostatic Neoplasms; Remission, Spontaneous; Stereotaxic Techniques; Testosterone

Topics: Acid Phosphatase; Agammaglobulinemia; Aged; Anemia, Myelophthisic; Blood Platelet Disorders; Bone Marrow Diseases; Diethylstilbestrol; Erythrocytes; Erythropoiesis; Half-Life; Humans; Iron; Iron Isotopes; L-Lactate Dehydrogenase; Leukocytes; Male; Neoplasm Metastasis; Osmotic Fragility; Prostatic Neoplasms; Remission, Spontaneous; Time Factors

Topics: Acid Phosphatase; Adrenalectomy; Alkaline Phosphatase; Castration; Cortisone; Estrogens; Follicle Stimulating Hormone; Humans; Hypophysectomy; Luteinizing Hormone; Male; Neoplasm Recurrence, Local; Prostatic Neoplasms; Remission, Spontaneous; Testosterone; Time Factors

Topics: 17-Ketosteroids; Acid Phosphatase; Adrenalectomy; Alkaline Phosphatase; Androgens; Bone Neoplasms; Cryosurgery; Follicle Stimulating Hormone; Follow-Up Studies; Growth Hormone; Humans; Hypophysectomy; Luteinizing Hormone; Male; Neoplasm Metastasis; Palliative Care; Pelvic Neoplasms; Prostatic Neoplasms; Remission, Spontaneous

Topics: Acid Phosphatase; Adult; Alkaline Phosphatase; Bone Marrow Examination; Female; Humans; Leukemia, Myeloid; Leukocyte Count; Leukocytes; Male; Muramidase; Nitrophenols; Remission, Spontaneous; Sarcoidosis